Johnson & Johnson (NYSE:JNJ) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings results on Wednesday. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.85 by $0.05, FiscalAI reports. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.02 billion. Johnson & Johnson updated its FY 2026 guidance to 11.600-11.750 EPS.

Johnson & Johnson Price Performance

JNJ stock opened at $253.70 on Wednesday. The business’s 50-day moving average is $238.18 and its two-hundred day moving average is $233.92. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a market capitalization of $610.71 billion, a P/E ratio of 29.33, a P/E/G ratio of 2.46 and a beta of 0.24. Johnson & Johnson has a 1 year low of $154.80 and a 1 year high of $269.43.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of JNJ. Brighton Jones LLC boosted its holdings in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Pinnacle Financial Partners Inc. grew its stake in shares of Johnson & Johnson by 16.0% during the 3rd quarter. Pinnacle Financial Partners Inc. now owns 209,915 shares of the company’s stock worth $38,923,000 after purchasing an additional 28,997 shares during the period. Schnieders Capital Management LLC. lifted its stake in shares of Johnson & Johnson by 9.8% in the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after purchasing an additional 6,584 shares during the period. United Bank grew its position in Johnson & Johnson by 32.7% during the second quarter. United Bank now owns 12,310 shares of the company’s stock worth $1,880,000 after buying an additional 3,031 shares during the period. Finally, Sivia Capital Partners LLC boosted its stake in shares of Johnson & Johnson by 13.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after acquiring an additional 692 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on JNJ. Weiss Ratings cut shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, June 15th. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a research report on Wednesday, April 15th. Argus increased their price objective on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $283.00 to $284.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. Finally, Wells Fargo & Company upped their price target on Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research report on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $261.26.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported Q2 results that beat Wall Street estimates, helped by strong performance in its medicines business, including Tremfya and Darzalex. Reuters article
• Positive Sentiment: The company raised FY 2026 EPS guidance to 11.60-11.75, slightly above consensus, and increased revenue guidance to $100.8 billion-$101.4 billion, signaling continued operational momentum. Business Wire article
• Positive Sentiment: Johnson & Johnson also declared a quarterly dividend of $1.34 per share, reinforcing its appeal as a defensive income stock. Business Wire dividend article
• Neutral Sentiment: Several pre-earnings previews had already highlighted J&J’s strong share performance and the chance for the stock to extend gains if results came in cleanly, which may have set a high bar. Barron’s article
• Negative Sentiment: Despite the beat and raised outlook, the stock slipped as investors appeared to take profits and react to limited upside versus already elevated expectations. Barron’s article

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.